Enjoy complimentary customisation on priority with our Enterprise License!
The anti-obesity drugs market size is forecast to increase by USD 18.33 billion at a CAGR of 14.44% between 2023 and 2028. The market is witnessing significant growth due to the global epidemic of energy imbalance, leading to an increase in calories consumed and expended disparities. This issue is particularly prevalent among children and adolescents, contributing to the rise of lifestyle-related illnesses such as cardiovascular disease. Factors such as stress, smoking, and drinking further exacerbate this trend. The market is driven by the research and development of drugs that target both obesity and type 2 diabetes mellitus. Additionally, the availability of anti-obesity devices through online pharmacies is increasing accessibility to these treatments. However, challenges remain, including the potential for side effects and the need for long-term adherence to treatment plans.
The anti-obesity drugs market, driven by the increasing prevalence of obesity and related chronic diseases, continues to grow. Obesity, characterized by an energy imbalance between calories consumed and calories expended, is a global endemic affecting millions. This condition is linked to various health issues, including insulin resistance, glucose intolerance, hypertension, sleep apnea, diabetes mellitus, arthritis, and lifestyle-related illnesses. Medicines for weight loss target multiple mechanisms, such as appetite suppression, metabolism enhancement, and fat absorption inhibition. Appetite suppression drugs help reduce food intake, while metabolism enhancers increase energy consumption. Fat absorption inhibitors prevent the body from absorbing dietary fats. Obesity-related diseases put a significant burden on healthcare systems worldwide. The prevalence of obesity continues to rise, fueled by factors like stress, smoking, and drinking. As a result, the demand for effective weight loss drugs is increasing. These drugs offer hope for those struggling with obesity and its associated health risks.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The class III anti-obesity drugs segment is estimated to witness significant growth during the forecast period. The Class III anti-obesity drugs segment dominates the global market and is expected to continue leading due to its focus on treating severe obesity. These prescription drugs primarily target patients with class III obesity, a condition characterized by a body mass index (BMI) of 40 or higher or a BMI of 35 or more with associated health issues. The pipeline for new anti-obesity drugs is strong, with several pharmaceutical companies investing in research and development. Class III anti-obesity drugs primarily function by affecting neurotransmitters like dopamine, norepinephrine, and serotonin, which regulate appetite and metabolism. These drugs can be administered through various routes, including the oral route and subcutaneous route, and are readily available at retail pharmacies. However, the growth rate of the Class III market may decelerate due to the increasing prevalence of morbid obesity and potential side effects, such as increased heart rate and blood pressure.
Get a glance at the market share of various segments Request Free Sample
The class III anti-obesity drugs segment accounted for USD 6.27 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 66% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
The market in North America is currently the largest and is anticipated to maintain its dominance throughout the forecast period. The market's growth can be attributed to the rising obese population in the region, particularly in the US, Mexico, and Canada. Approved drugs such as Qsymia, Saxenda, and BELVIQ have generated significant revenues in North America due to their effectiveness in managing weight by regulating blood pressure, heart rate, and serotonin activity. These drugs are available in both oral and subcutaneous routes, making them easily accessible through retail pharmacies. However, the growth momentum of the North American market is expected to decelerate during the forecast period, despite the continued presence of a large obese population. The drugs in the pipeline phase include those that target dopamine and norepinephrine, which could potentially offer new treatment options and drive market growth.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The growing obese population is the key driver of the market. Obesity, a significant public health concern worldwide, is linked to health behaviors and chronic conditions such as diabetes, hypertension, and cancer. The global prevalence of obesity and overweight populations has risen due to the limited effectiveness of current treatments. The United States has reported the highest prevalence of obesity over the past two decades. Factors contributing to this trend include sedentary lifestyles and insufficient physical activity, leading to an increase in health issues like obesity, cardiovascular diseases, and diabetes.
In response, consumers are becoming more health-conscious and seeking effective weight-loss solutions. Medications for weight loss target various mechanisms, including appetite suppression, metabolism enhancement, and fat absorption inhibition. These drugs aim to reduce food intake and increase energy consumption, thereby aiding weight loss.
Research on drugs that target both obesity and type 2 diabetes mellitus is the upcoming trend in the market. The global health concern of obesity and type 2 diabetes continues to escalate, with both conditions linked to metabolic disorders such as hypertension, dyslipidemia, and insulin resistance, leading to an increased risk of cardiovascular diseases. Obesity is indicated by a high Body Mass Index (BMI), and it is a significant risk factor for type 2 diabetes mellitus. Insulin resistance, a condition where the body's cells do not respond effectively to insulin, is a common factor linking obesity and type 2 diabetes.
Further, tne potential solution to address this epidemic is through the use of weight-loss medicines. AstraZeneca's drug, MEDI0382, is currently undergoing clinical trials in its phase II development for the treatment of both obesity and type 2 diabetes mellitus. This medication targets appetite suppression and fat absorption, ultimately reducing food intake and increasing energy consumption. By addressing the root causes of obesity and type 2 diabetes, drugs like MEDI0382 hold promise in preventing and managing these metabolic syndromes.
The availability of anti-obesity devices is a key challenge affecting the market growth. Obesity, a prevalent lifestyle disease, poses significant health risks including cardiovascular diseases, strokes, and hypertension. Preventive measures, such as physical activities and weight loss supplements, are often recommended for individuals with early-stage obesity. However, in advanced cases, weight loss may prove elusive despite these efforts. In such situations, anti-obesity drugs emerge as viable solutions. These medicines work by influencing various mechanisms, including appetite suppression, metabolism enhancement, and fat absorption inhibition.
Further, by reducing food intake and increasing energy consumption, these drugs help individuals manage their weight. The obesity market is witnessing considerable growth due to the increasing prevalence of obesity and overweight conditions worldwide. According to recent statistics, over 1.9 billion adults were reported to be overweight or obese in 2016. This growing trend is expected to fuel the demand for weight loss medicines in the coming years.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Alvogen Iceland ehf - The company offers Qsymia medicine as a precription which is designed for the treatnent for obesity disease.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Obesity, a chronic condition characterized by excessive accumulation of body fat, is a global health concern with increasing prevalence due to unhealthy diets, sedentary lifestyles, and other lifestyle-related factors. The market for weight-loss medicines has witnessed significant growth due to the rising burden of obesity-related chronic diseases such as heart disease, diabetes, cancer, and insulin resistance. These conditions are linked to energy imbalance, where calories consumed exceed calories expended. Weight-loss medicines work by affecting various mechanisms, including appetite suppression, metabolism enhancement, and fat absorption inhibition. Prescription drugs, like those acting on dopamine, norepinephrine, and serotonin activity, are in different pipeline phases. The market includes various drug types, administered through oral and subcutaneous routes, available in retail pharmacies and online pharmacies. Obesity is associated with numerous health complications, including high blood pressure, heart rate, sleep apnea, diabetes mellitus, arthritis, gall bladder diseases, and obesity-associated cancers like breast cancer and colorectal cancer.
Further, the World Obesity Federation reports that over 650 million adults and 124 million children and adolescents are obese or overweight. Telemedicine and over-the-counter (OTC) drugs are emerging trends in obesity care. The ideal anti-obesity medicine should promote sustained weight loss while minimizing side effects and addressing the root causes of obesity. Obesity is a significant contributor to severe illness and death and disability, with cardiovascular disease, cancers, and type-2 diabetes being the leading causes. Stress, smoking, and drinking are also contributing factors. The global endemic of obesity necessitates the development of effective and safe anti-obesity medicines to mitigate the burden of lifestyle-related illnesses.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
166 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 14.44% |
|
Market Growth 2024-2028 |
USD 18.33 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
12.32 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 66% |
|
Key countries |
US, Germany, UK, Canada, and China |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Alvogen Iceland ehf, Amgen Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Eli Lilly and Co., Empros Pharma AB, ERX Pharmaceuticals Inc., Gelesis Inc., GlaxoSmithKline Plc, Innovent Biologics Inc., LG Chem Ltd., Novo Nordisk AS, Rhythm Pharmaceuticals Inc., SCOHIA PHARMA Inc., VIVUS LLC, and Zydus Lifesciences Ltd. |
|
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Drug Class
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
